PRINTER'S NO. 1591

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE RESOLUTION

No.

295

Session of

2018

INTRODUCED BY SCHWANK, DINNIMAN, FONTANA, GREENLEAF, BREWSTER,

BARTOLOTTA, BROWNE, FOLMER, KILLION, BAKER, FARNESE,

RAFFERTY, MENSCH, COSTA, HUGHES, BOSCOLA, AUMENT AND

causes abnormal cell growth of the arterial walls in the body

and can lead to areas of narrowing, beading, aneurysms and

tearing of areas of the arterial wall; and

WHEREAS, FMD is usually detected by accident or as a result

of a serious incident because its symptoms, including

hypertension, headaches and dizziness, affect much of the

general population; and

WHEREAS, There has been little progress in understanding the

disease since it was first diagnosed in 1938; and

WHEREAS, There is no known cause or cure for the disease, and

two most common types being medial fibroplasia and intimal

fibroplasia, but there is no understanding of what causes the

differences; and

WHEREAS, Unlike the adult population, children tend to be

diagnosed with intimal fibroplasia, a more aggressive disease;

and

WHEREAS, Individuals and families affected by fibromuscular

dysplasia often experience problems such as a sense of

isolation, difficulty in obtaining accurate and timely diagnosis

and optimal treatment options; and

disease; and

WHEREAS, The Fibromuscular Dysplasia Society of America

(FMDSA) was founded in March 2003 and over the past 14 years has

been active and successful in raising public and medical

professional awareness of the disease, increasing patient

support and working with researchers around the world; and

WHEREAS, FMDSA is also funding the United States Registry for

Fibromuscular Dysplasia; and

WHEREAS, FMDSA is organizing a global observance of FMD to

have patients, medical professionals and researchers join